Introduction {#sec1-1}
============

In Thailand, cancers are the commonest cause of death, being higher than cardiovascular events and trauma. Cancer of the ampulla of Vater is one of the periampullary cancers (cancer of ampulla of Vater, distal common bile duct, pancreas and duodenum). Cancer of the ampulla of Vater is uncommon, accounting for 0.2% of gastrointestinal malignancies and 6% of periampullary cancers.(Jemal et al., 2008) Although it has the best survival compared to other periampullary cancers the five year survival rate ranges from 36.8 to 78.8% and has not improved for the past two decades.(Talamini et al., 1997; Howe et al., 1998; Duffy et al., 2003; Bettschart et al., 2004; Brown et al., 2005; Di Giorgio et al., 2005; Riall et al., 2005; Yoon et al., 2005; Kim et al., 2006)

A recent study from China reported survival rate and prognostic factors which affect the survival rate of ampulla of Vater carcinoma in patients after pancreaticoduodenectomy.(Zhou et al., 2014) The prognostic factors identified are pancreatic invasion, lymph node metastasis and elevated CA19-9 level. There are several studies revealed T stage, tumor differentiated and chemotherapy also identified as prognostic factors(Talamini et al., 1997; Howe et al., 1998; Duffy et al., 2003; Di Giorgio et al., 2005; Kim et al., 2006; Woo et al., 2007; O'Connell et al., 2008) but there is no reported data in Thai people.

The primary aim of this study was to report the survival rate of ampulla of Vater carcinoma patients in Thailand and the secondary aim was to investigate prognostic factors which influenced the survival rate.

Material and Methods {#sec1-2}
====================

All patients diagnosed with ampulla of Vater carcinoma at Chiang Mai University Hospital from 2005 to 2012 were retrospectively analyzed (72 patients included). Radical resection (Whipple's operation or pyloric preserving pancreaticoduodenectomy) was done in all patients. The area of lymph node dissection was performed by removal of all tissue around hepatoduodenal ligament (station 12), along common hepatic artery (station 8) and highest peri-pancreatic lymph node (station 13). The specimens were sent to pathologists for confirmation of the diagnosis and TNM staging was identified according to the American Joint Committee on Cancer (AJCC) 7th Ed. staging system. The patients who had received palliative bypass, resection or had distant metastasis were excluded from the study. The data analysis included survival rate, tumor size, T staging, lymph node metastasis, tumor staging, free margin, tumor differentiation, elevated CA19-9, jaundice, waiting time for surgery, time to recurrence and chemotherapy. Almost of the patients who were jaundiced (total bilirubin more than 3 mg/dl) underwent percutaneous transhepatic biliary drainage (PTBD) or endoscopic retrograde cholangiopancreatography(ERCP) with internal stent before surgery.

Statistical analysis {#sec2-1}
--------------------

A t-test/Mann Whitney U test were used to analyze the quantitative variables, Fisher's exact test was used for the analysis of qualitative variables. The time to event analysis was performed for survival comparisons. Cox's proportional hazard, univariate and multivariate analysis were performed to identify prognostic factors. A p-value of \< 0.005 was regarded as statistically significant.

Results {#sec1-3}
=======

There were 72 CAV patients included in the study. 12 out of 72 patients (16.7%) were lost to follow up in one year after surgery. Four patients (5.6%) were dead within 30 days after surgery; two from anastomosis bleeding, one from pneumonia and one from sepsis. There were more female patients than male (54.2% vs. 45.8%). Mean age was 65.2 years old. Patients usually presented with elevated CA 19-9 (61.1%), jaundice (66.7%) and without comorbidities (59.3%) regards to Charlson comorbidity index. (Quan et al., 2011) Median waiting time for surgery was 56.5 days (Interquartile range (IQR) 24.5-91.5). There was no difference in waiting time in jaundiced and none-jaundiced patients. Overall recurrence rate was 30.6% (22 patients). 36.3% of patients with recurrence received chemotherapy treatment (8 out of 22 patients) ([Table 1](#T1){ref-type="table"}).

###### 

Baseline Characteristics and Overall Descriptive Data of CAV Patients

  Baseline characteristics           N = 72
  ---------------------------------- ------------------
  Gender, n (%)                      
   Male                              33 (45.8)
   Female                            39 (54.2)
  Age, mean + SD                     65.1 + 10.5
  Tumor size (cm), n (%)             
   \< 2.0                            20 (27.8)
   ≥ 2.0                             52 (72.2)
  T staging, n (%)                   
   Stage 1                           8 (11.1)
   Stage 2                           31 (43.1)
   Stage 3                           17 (23.6)
   Stage 4                           16 (22.2)
  N staging, n (%)                   
   Stage 0                           46 (63.9)
   Stage 1                           26 (36.1)
  TNM Stage, n (%)                   
   IA                                8 (11.1)
   IB                                21 (29.2)
   IIA                               9 (12.5)
   IIB                               18 (25.0)
   III                               16 (22.2)
  Free margin, n (%)                 
   Yes                               71 (98.6)
   No                                1 (1.4)
  Tumor differentiation, n (%)       
   Well differentiated               60 (83.3)
   Moderately                        11 (15.3)
   Poorly differentiated             1 (1.4)
  CA19-9 (μ/mL), n (%)               
   0--37                             28 (38.9)
   \> 37                             44 (61.1)
  Total bilirubin (mg/dL), n (%)     
   \< 3                              24 (33.3)
   ≥ 3                               48 (66.7)
  Waiting time (min), median (IQR)   56.5 (24.5-91.5)
  30-day mortality, n (%)            4 (5.6)
  Recurrence, n (%)                  22 (30.6)
  Chemotherapy, n (%)                8 (11.1)
  Median survival time (month)       75.3
  5-year survival, n/N (%)           24/72 (33.3)

N stage 0, No lymph node metastasis; N stage 1, Lymph node metastasis; IQR, Interquartile range

Nearly three quarters of patients had a tumor size of more than 2 cm (72.2%). Using TNM staging, the distribution of patients was stage IA 11.1%, stage IB 29.2%, stage IIA 12.5%, stage IIB 25% and stage III 22.2%. 36.2% of patients had lymph node metastasis. The majority of tumors were well differentiated (83.3%). Only one patient was margin positive (R1 resection) ([Table 1](#T1){ref-type="table"}).

There were 22 patients who had recurrence of disease. In this group, 13 patients (50%) had lymph node metastasis and 15 patients (44.1%) had advanced TNM staging (stage IIB and III). These two groups had a statistically significant higher rate of recurrence (50% (p = 0.015) and 44.1% (p = 0.023)). While T staging showed no statistical significance.

Baseline characteristics and tumor factors had been analyzed to know the distribution of number in dead and alive patients. These had shown the possible prognostic factors in the next step of data analysis ([Table 2](#T2){ref-type="table"}).

###### 

Prognostic Factors for CAV Patients after Surgery

  Prognostic factors                 Dead (N = 36)   Alive (N = 36)   p value
  ---------------------------------- --------------- ---------------- ----------
  Gender, n (%)                                                       1
   Male                              16 (48.5)       17 (51.5)        
   Female                            20 (51.3)       19 (48.7)        
  Age (mean + SD)                    66.3 + 10.9     63.9 + 10.1      0.333
  Comorbidity, n (%)                                                  0.023
   Yes                               17 (70.8)       7 (29.2)         
   No                                19 (39.6)       29 (60.4)        
  Waiting time (day), median (IQR)   43 (17-88)      65.5 (30.5-96)   0.253
  Loss FU, n (%)                                                      0.343
   Yes                               8 (66.7)        4 (33.3)         
   No                                28 (46.7)       32 (53.3)        
  Tumor size (cm), n (%)                                              0.017
   \< 2.0                            5 (25)          15 (75)          
   ≥ 2.0                             31 (59.6)       21 (40.4)        
  T staging, n (%)                                                    0.477
   Stage 1                           2 (25)          6 (75)           
   Stage 2                           17 (54.8)       14 (45.2)        
   Stage 3                           8 (47.1)        9 (52.9)         
   Stage 4                           9 (56.3)        7 (43.7)         
  N staging, n (%)                                                    0.026
   Stage 0                           18 (39.1)       28 (60.9)        
   Stage 1                           18 (69.2)       8 (30.8)         
  TNM stage, n (%)                                                    0.238
   Early stage                       16 (42.1)       22 (57.9)        
   Advanced stage                    20 (58.8)       14 (41.2)        
  Margin, n (%)                                                       1
   Negative                          35 (49.3)       36 (50.7)        
   Positive                          1 (100)         0                
  Tumor differentiation, n (%)                                        0.111
   Well differentiated               27 (45)         33 (55)          
   Moderately differentiated         8 (72.7)        3 (27.3)         
   Poorly differentiated             1 (100)         0                
  CA19-9 (μ/mL), n (%)                                                1
   0--37                             14 (50)         14 (50)          
   \> 37                             22 (50)         22 (50)          
  Total bilirubin (mg/dL), n (%)                                      0.211
   \< 3                              15 (62.5)       9 (37.5)         
   ≥ 3                               21 (43.7)       27 (56.3)        
  Chemotherapy, n (%)                                                 0.26
   Yes                               6 (75)          2 (25)           
   No                                30 (46.9)       34 (53.1)        
  Recurrence, n (%)                                                   \< 0.001
   Yes                               20 (90.9)       2 (9.1)          
   No                                16 (32)         34 (68)          

From the univariate analysis, the prognostic factors that effected survival were comorbidities (HR 2.62, 95% CI 1.36-5.06, p = 0.004), tumor size more than 2 cm (HR 3.11, 95% CI 1.21-8.02, p = 0.019), lymph node metastasis (HR 2.65, 95% CI 1.37-5.13, p = 0.004) and recurrence (HR 5.71, 95% CI 2.76-11.80, p \< 0.001) ([Table 3](#T3){ref-type="table"}).

###### 

Univariate Analysis for Prognostic Factors for CAV Patients after Surgery

  Factors                                Crude Hazard ratio   95% CI        p-value
  -------------------------------------- -------------------- ------------- ----------
  Comorbidity                            2.62                 1.36-5.06     0.004
  Tumor size ≥ 2.0 cm                    3.11                 1.21-8.02     0.019
  T staging                              1.28                 0.90-1.81     0.165
  N Stage 1                              2.65                 1.37-5.13     0.004
  TNM advanced stage                     1.84                 0.95-3.56     0.07
  Positive margin                        13.69                1.60-117.21   0.017
  Moderate and poor differentiation      2.97                 1.38-6.42     0.006
  Elevated CA19-9 (\>37 μ/mL)            1.02                 0.52-1.99     0.957
  Jaundice (total bilirubin ≥ 3 mg/dL)   0.71                 0.37-1.38     0.311
  Chemotherapy                           1.94                 0.80-4.73     0.144
  Recurrence                             5.71                 2.76-11.80    \< 0.001

According to the multivariate analysis, recurrence (HR 5.90, 95% CI 2.71-12.84, p \< 0.001), moderate and poor differentiation (HR 4.88, 95% CI 2.08-11.48.65, p \< 0.001), comorbidity (HR 3.98, 95% CI 1.94-8.18, p \< 0.001) and tumor size \> 2.0 cm (HR 2.75, 95% CI 1.04-7.25, p = 0.041) were potential prognostic factors for the survival of CAV patients ([Table 4](#T4){ref-type="table"}).

###### 

Multivariate Analysis for Potential Prognostic Factors for CAV Patients after Surgery

  Factors                             Adjusted   95% Confidence interval   p value
  ----------------------------------- ---------- ------------------------- ----------
  Recurrence                          5.9        2.71-12.84                \< 0.001
  Moderate and poor differentiation   4.88       2.08-11.48                \< 0.001
  Comorbidity                         3.98       1.94-8.18                 \< 0.001
  Tumor size \> 2.0 cm                2.75       1.04-7.25                 0.041

Overall 5 year survival rate of CAV patients was 33.3 months. Although overall median survival time was 75.3 months ([Figure 1](#F1){ref-type="fig"}). The trend was that the early stages (stage IA, IB and IIA) had a higher median survival time than the advanced stages (stage IIB and III) (78.9 vs. 30.3 months, p = 0.066) ([Figure 1A](#F1){ref-type="fig"}). Median survival times for patients with lymph node metastasis was 24 months which was significantly poorer than lymph node negative group (p = 0.003) ([Figure 1B](#F1){ref-type="fig"}). Median survival times for patients with recurrence was 23 months ([Figure 2A](#F2){ref-type="fig"}), patients with moderate or poor differentiation was 16.6 months ([Figure 2B](#F2){ref-type="fig"}), patients with comorbidities was 21.3 months ([Figure 2C](#F2){ref-type="fig"}) and a tumor size of more than 2 cm patients was 38.5 months ([Figure 2D](#F2){ref-type="fig"}).
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Discussion {#sec1-4}
==========

For many decades the outcomes for patients with carcinoma of the ampulla of Vater were unimpressive. The complete removal of the tumor by surgery was a key to prolonging the survival of patients. From the 1980s, local resection for early CAV patients was interesting topic but it had 10% of lymph node metastasis in early stage. (Clary et al., 2000; Dixon et al., 2005; Demetriades et al., 2006; Lee et al., 2006; Yoon et al., 2007) Then, the risks and benefits might be adjusted for individual patients. In this study, the median overall survival time was 75.3 months which was comparable to a study from Di Giorgio(Di Giorgio et al., 2005) The postoperative mortality was higher than a recent study from China (5.6% vs. 4.32%)(Zhou et al., 2014).

In this study, all CAV patients with jaundice had the procedure preoperative PTBD or ERCP with internal stent performed and the bilirubin was checked until it was within normal limits before surgery(Abdullah et al., 2009). The waiting time in both jaundiced and none jaundiced patients were no different. This means that the preoperative biliary drainage procedure did not delay surgery and also that the waiting time was too long. One way to improve the outcome for the non-jaundiced patients would be to reduce the waiting time.

After surgery, there was no adjuvant chemotherapy. Again a possibility for the improvement of survival rates may be to use chemotherapy in high risk patients. (Narang et al., 2011) The high risk patients from this study refers to the patients who had poor prognostic factors such as moderate or poor differentiation, large tumor size of more than 2 cm and lymph node metastasis which related to dead. Recurrence of tumor is obviously a key factor for poor survival. Once the patients had recurrence, the survival couldn't reach five years. It would be useful for a future study to focus on this.

Chemotherapy treatment in this study was restricted to recurrent patients. The surgeons sent recurrent patients to an oncologist who made the decision regarding chemotherapy treatment. Only 36.3% (8 of 22) of recurrent patients can receive chemotherapy. Majority of recurrent patients had poor performance status after recurrence was detected. There are rooms for improvement in follow up care. If it is possible to detect recurrence more earlier, we might achieve better survival in recurrent group.

There were many limitations in this study. First, this was a retrospective study, secondly, there was loss to follow up a significant number of patients (12 of 72, 16.7%) which meant this data was collected by phone, thirdly, the study had fewer CAV patients than the previous study and lastly the chemotherapy was only offered to some recurrent patients. If adjuvant chemotherapy was used the survival rate might be better.

The findings of this study indicate that the overall survival rate of CAV patients after surgery was quite fair (5 year survival rate = 33.3%), and the trend to better survival is in early stages when compared to advanced stages especially in lymph node negative group. The key prognostic factors were recurrence, moderate and poor differentiation, comorbidity and tumor size \> 2.0 cm.
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